Arterial therapy of hepatic colorectal metastases

British Journal of Surgery

Volumn 83, Issue 4, 1996, Pages 447-455

  Vauthey, J N ^a,b   Marsh, R De W ^a   Cendan, J C ^a   Chu, N M ^a   Copeland, E M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; MITOMYCIN;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG TOXICITY; HEPATIC ARTERY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER METASTASIS; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; RANDOMIZED CONTROLLED TRIALS;

EID: 0029987826     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.1800830405     Document Type: Review

References (104)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995; 45: 8-30.
2. Kemeny N, Niedzwiecki D, Shurgot B, Oderman P. Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement. Cancer 1989; 63: 742-7.
3. Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987; 107: 459-65.
4. Bengmark S, Hafström L. The natural history of primary and secondary malignant tumors of the liver: I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 1969; 23: 198-202.
5. Oxley EM, Ellis H. Prognosis of carcinoma of the large bowel in the presence of liver metastases. Br J Surg 1969; 56: 149-52.
6. Wood CB, Gillis CR, Blumgart LH. A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol (R Coll Radiol) 1976; 2: 285-8.
7. Bengtsson G, Carlsson G, Hafström L, Jonsson PE. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1981; 141: 586-9.
8. Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 1984; 199: 502-8.
9. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994; 343: 1405-10.
10. Nordlinger B, Jaeck D, Guiguet M et al. Surgical resection of hepatic metastases. Multicentric retrospective study of the French Association of Surgery. In: Nordlinger B, Jaeck D, eds. Treatment of Hepatic Metastases of Colorectal Cancer. Paris: Springer, 1992: 129-46.
11. Hughes KS, Simon R, Songhorabodi S et al. Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of patterns of recurrence. Surgery 1986; 100: 278-84.
12. Gayowski TJ, Iwatsuki S, Madariaga JR et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 1994; 116: 703-11.
13. Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 1991; 110: 13-29.
14. Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-8.
15. Wolmark N, Rockette H, Fisher B et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993; 11: 1879-87.
16. O'Connell M, Mailliard J, Macdonald J et al. An intergroup trial of intensive course 5FU and low dose leucovorin as surgical adjuvant therapy for high risk colon cancer. Proceedings of the American Society of Clinical Oncology 1993; 12: 190.
17. Zaniboni A, Erlichman C, Seitz JF et al. FUFA increases disease-free survival (DFS) in resected B2C colon cancer (CC): results of a prospective pooled analysis of 3 randomised trials (RCTs). Proceedings of the American Society of Clinical Oncology 1993; 12: 191.
18. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994; 330: 1136-42.
19. Buroker T, Kim PN, Groppe C et al. 5FU infusion with mitomycin-C vs. 5FU infusion with methyl-CCNU in the treatment of advanced colon cancer: a Southwest Oncology Group study. Cancer 1978; 42: 1228-33.
20. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial. J Clin Oncol 1989; 7: 1437-46.
21. Kemeny N, Younes A, Seiter K et al. Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity. Cancer 1990; 66: 2470-5.
22. Klopp CT, Alford TC, Bateman J, Berry GN, Winship T. Fractionated intra-arterial cancer: chemotherapy with methyl bis amine hydrochloride; a preliminary report. Ann Surg 1950; 132: 811-32.
23. Clarkson B, Young C, Dierick W et al. Effects of continuous hepatic artery infusion of antimetabolites on primary and metastatic cancer of the liver. Cancer 1962; 15: 472-88.
24. Brennan MJ, Talley RW, Drake EH, Vaitkevicus VK, Poznanski AK, Brush BE. 5-Fluorouracil treatment of liver metastases by continuous hepatic artery infusion via Cournand catheter: results and suitability for intensive postsurgical adjuvant chemotherapy. Ann Surg 1963; 158: 405-19.
25. Sullivan RD, Zurek WZ. Chemotherapy for liver cancer by protracted ambulatory infusion. JAMA 1965; 194: 481-6.
26. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954; 30: 969-85.
27. Ackerman NB. The blood supply of experimental liver metastases: IV. Changes in vascularity with increasing tumor growth. Surgery 1974; 75: 589-96.
28. Sigurdson ER, Ridge JA, Kemeny N, Daly JM. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 1987; 5: 1836-40.
29. Ensminger WD, Gyves JW. Regional chemotherapy of neoplastic diseases. Pharmacol Ther 1983; 21: 277-93.
30. Ensminger WD, Rosowsky A, Raso V et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res 1978; 38: 3784-92.
31. Lee YT. Regional management of liver metastases. I. Cancer Invest 1983; 1: 237-57.
32. Watkins E Jr, Khazei AM, Nahra KS. Surgical basis for arterial infusion chemotherapy of disseminated carcinoma of the liver. Surg Gynecol Obstet 1970; 130: 581-605.
33. Oberfield RA, McCaffrey JA, Polio J, Clouse ME, Hamilton T. Prolonged and continuous percutaneous intra-arterial hepatic infusion chemotherapy in advanced metastatic liver adenocarcinoma from colorectal primary. Cancer 1979; 44: 414-23.
34. Clouse ME, Ahmed R, Ryan RB, Oberfield RA, McCaffrey JA. Complications of long term transbrachial hepatic arterial infusion chemotherapy. AJR Am J Roentgenol 1977; 129: 799-803.
35. Ramming KP, Haskell CM, Tesler AS. Gastrointestinal tract neoplasms. Section 8: Management of lesions metastatic to the liver. In: Haskell CM, ed. Cancer Treatment. Philadelphia, Pennsylvania: WB Saunders, 1980: 325-34.
36. Cady B. Hepatic arterial patency and complications after catheterization for infusion chemotherapy. Ann Surg 1973; 178: 156-61.
37. Patt YZ, Mavligit GM. Arterial chemotherapy in the management of colorectal cancer: an overview. Semin Oncol 1991; 18: 478-90.
38. Morris DL, Horton MDA'C, Dilley AV, Warlters A, Clingan PR. Treatment of hepatic metastases by cryotherapy and regional cytotoxic perfusion. Gut 1993; 34: 1156-7.
39. Curley SA, Roh MS, Chase JL, Hohn DC. Adjuvant hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases. Am J Surg 1993; 166: 743-8.
40. Curley SA, Chase JL, Roh MS, Hohn DC. Technical considerations and complications associated with the placement of 180 implantable hepatic arterial infusion devices. Surgery 1993; 114: 928-35.
41. Hunt TM, Flowerdew ADS, Birch SJ, Williams JD, Mullee MA, Taylor I. Prospective randomized controlled trial of hepatic arterial embolization or infusion chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases. Br J Surg 1990; 77: 779-82.
42. Doci R, Bignami P, Quagliuolo V et al. Continuous hepatic arterial infusion with 5-fluorodeoxyuridine for treatment of colorectal metastases. Regional Cancer Treatment 1990; 3: 13-18.
43. Blackshear PJ, Dorman FD, Blackshear PL Jr, Varco RL, Buchwald H. A permanently implantable self-recycling low flow constant rate multipurpose infusion pump of simple design. Surgical Forum 1970; 21: 136-7.
44. Blackshear PJ, Dorman FD, Blackshear PL Jr, Varco RL, Buchwald H. The design and initial testing of an implantable infusion pump. Surg Gvnecol Obstet 1972; 134: 51-6.
45. Blackshear PJ, Rohde TD, Varco RL, Buchwald H. One year of continuous heparinization in the dog using a totally implantable infusion pump. Surg Gynecol Obstet 1975; 141: 176-86.
46. Buchwald H, Grage TB, Vassilopoulos PP, Rohde TD, Varco RL, Blackshear PJ. Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump. Cancer 1980; 45: 866-9.
47. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994; 344: 1255-60.
48. Patt YZ. Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver: the controversy continues. J Clin Oncol 1993; 11: 815-19.
49. Safi F, Bittner R, Roscher R, Schumacher K, Gaus W, Beger GH. Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarterial versus continuous intraarterial/intravenous therapy): results of a controlled clinical trial. Cancer 1989; 64: 379-87.
50. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206: 685-93.
51. Hohn DC, Stagg RJ, Friedman MA et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989; 7: 1646-54.
52. Martin JK Jr, O'Connell MJ, Wieand HS et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990; 125: 1022-7.
53. Rougier P, Laplanche A, Huguier M et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992; 10: 1112-18.
54. Lefor AT, Hughes KS, Shiloni E et al. Intra-abdominal extrahepatic disease in patients with colorectal hepatic metastases. Dis Colon Rectum 1988; 31: 100-3.
55. Bahineau TJ, Lewis WD, Jenkins RL, Bleday R, Steele GD Jr, Forse RA. Role of staging laparoscopy in the treatment of hepatic malignancy. Am J Surg 1994; 167: 151-5.
56. John TG, Greig JD, Crosbie JL, Miles WF, Garden OJ. Superior staging of liver tumours with laparoscopy and laparoscopic ultrasound. Ann Surg 1994; 220: 711-19.
57. Cohen AM, Kaufman SD, Wood WC, Greenfield AJ. Regional hepatic chemotherapy using an implantable drug infusion pump. Am J Surg 1983; 145: 529-33.
58. Hiatt JR, Gabbay J, Busuttil RW. Surgical anatomy of the hepatic arteries in 1000 cases. Ann Surg 1994; 220: 50-2.
59. Curley SA, Hohn DC, Roh MS. Hepatic artery infusion pumps: cannulation techniques and other surgical considerations. Langenbecks Arch Chir 1990; 375: 119-24.
60. Cohen AM, Higgins J, Waltman AC, Athanasoulis C, McKusick K. Effect of ligation of variant hepatic arterial structures on the completeness of regional chemotherapy infusion. Am J Surg 1987; 153: 378-80.
61. Campbell KA, Burns RC, Sitzmann JV, Lipsett PA, Grochow LB, Niederhuber JE. Regional chemotherapy devices: effect of experience and anatomy on complications. J Clin Oncol 1993; 11: 822-6.
62. Kemeny MM, Battifora H, Blayney DW et al. Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. Ann Surg 1985; 202: 176-81.
63. Kemeny N, Sigurdson ER. Intra-arterial chemotherapy for liver tumours. In: Blumgart LH, ed. Surgery of the Liver and Biliary Tract. 2nd ed. Vol. 2. Edinburgh: Churchill Livingstone, 1994: 1473-91.
64. Johnson LP, Wasserman PB, Rivkin SE. FUDR hepatic arterial infusions via an implantable pump for treatment of hepatic tumors. Proceedings of the Amerian Society of Clinical Oncology 1983; 2: 119.
65. Weiss GR, Garnick MB, Osteen RT et al. Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump. J Clin Oncol 1983; 1: 337-44.
66. Kemeny N, Daly J, Oderman P et al. Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol 1984; 2: 595-600.
67. Niederhuber JE, Ensminger W, Gyves J, Thrall J, Walker S, Cozzi E. Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer 1984; 53: 1336-43.
68. Schwartz SI, Jones LS, McCune CS. Assessment of treatment of intrahepatic malignancies using chemotherapy via an implantable pump. Ann Surg 1985; 201: 560-7.
69. Shepard KV, Levin B, Karl RC et al. Therapy for metastatic colorectal cancer with hepatic artery infusion chemotherapy using a subcutaneous implanted pump. J Clin Oncol 1985; 3: 161-9.
70. Balch CM, Urist MM. Intraaarterial chemotherapy for colorectal liver metastases and hepatomas using a totally implantable drug infusion pump. Recent Results Cancer Res 1986; 100: 234-47.
71. Wagman LD, Kemeny MM, Leong L et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 1990; 8: 1885-93.
72. Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984; 2: 498-504.
73. Patt YZ, Roh M, Chase J et al. A phase I trial of hepatic arterial infusion (HAI) of floxuridine (FUDR) and folinic acid (FA) for colorectal cancer (CRC) metastatic to the liver. Proceedings of the American Society of Clinical Oncology 1990; 9: 118.
74. Kemeny N, Cohen A, Bertino JR, Sigurdson ER, Botet J, Oderman P. Continuous intrahepatic infusion of floxuridine and leucovorin through an implantable pump for the treatment of hepatic metastases from colorectal carcinoma. Cancer 1990; 65: 2446-50.
75. Kemeny N, Seiter K, Conti JA et al. Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update. Cancer 1994; 73: 1134-42.
76. Kemeny N, Conti JA, Cohen A et al. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 1994; 12: 2288-95.
77. Patt YZ, Boddie AW Jr, Charnsangavej C et al. Hepatic arterial infusion with floxuridine and cisplatin: overriding importance of antitumor effect versus degree of tumor burden as determinants of survival among patients with colorectal cancer. J Clin Oncol 1986; 4: 1356-64.
78. Arisawa Y, Sutanto-Ward E, Dalton RR, Sigurdson ER. Short-term intrahepatic FUdR infusion combined with bolus mitomycin C: reduced risk for developing drug resistance. J Surg Oncol 1994; 56: 75-80.
79. Jones DV Jr, Patt YZ, Chase J et al. A pilot study of 5-fluorouracil (5FU) and recombinant human alpha interferon (αIFN) by hepatic arterial infusion (HAI) for patients (PTS) with colorectal cancer (CRC) metastatic to the liver. Proceedings of the American Society of Clinical Oncology 1993; 12: 216.
80. Mavligit GM, Zukiwski AA, Gutterman JU, Salem P, Charnsangevej C, Wallace S. Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastases. J Clin Oncol 1990; 8: 319-24.
81. Mavligit GM, Zukiwski AA, Wallace S. Tumor regression after hepatic arterial infusion of recombinant tumor necrosis factor in patients with colon carcinoma metastatic to the liver. Proceedings of the American Society of Clinical Oncology 1990; 9: 118.
82. Kaplan WD, Come SE, Takvorian RW et al. Pulmonary uptake of technetium 99m macroaggregated albumin: a predictor of gastrointestinal toxicity during hepatic artery perfusion. J Clin Oncol 1984; 2: 1266-9.
83. Hohn DC, Stagg RJ, Price DC, Lewis BJ. Avoidance of gastroduodenal toxicity in patients receiving hepatic arterial 5-fluoro-2′-deoxyuridine. J Clin Oncol 1985; 3: 1257-60.
84. Kemeny NE. Is hepatic infusion of chemotherapy effective treatment for liver metastases? Yes! In: DeVita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia, Pennsylvania: JB Lippincott, 1992: 207-27.
85. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
86. Doria MI Jr, Shepard KV, Levin B, Riddell RH. Liver pathology following hepatic arterial infusion chemotherapy. Hepatic toxicity with FUDR. Cancer 1986; 58: 855-61.
87. Pettavel J, Gardiol D, Bergier N et al. Necrosis of main bile ducts caused by hepatic artery infusion of 5-fluoro-2-deoxyuridine: a prospective study of enzymatic, radiologic and histologic changes in 13 patients infused in 1984-1986. Regional Cancer Treatment 1988; 1: 83-92.
88. Gluck WL, Akwari OE, Kelvin FM, Goodwin BJ. A reversible enteropathy complicating continuous hepatic artery infusion chemotherapy with 5-fluoro-2-deoxyuridine. Cancer 1985; 56: 2424-7.
89. Grage TB, Vassilopoulos PP, Shingleton WW et al. Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil versus intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer: a Central Oncology Group study. Surgery 1979; 86: 550-5.
90. Marks RG. Designing a Research Project: The Basis of Biomedical Research Methodology. New York: Van Nostrand-Reinhold C, 1989.
91. Ramming KP, Sparks FC, Eilber FR, Holmes EC, Morton DL. Hepatic artery ligation and 5-fluorouracil infusion for metastatic colon carcinoma and primary hepatoma. Am J Surg 1976; 132: 236-42.
92. Taylor I. Cytotoxic perfusion for colorectal liver metastases. Br J Surg 1978; 65: 109-14.
93. Berjian RA, Douglass HO Jr, Nava HR, Karakousis C. The role of hepatic artery ligation and dearterialization with infusion chemotherapy in advanced malignancies in the liver. J Surg Oncol 1980; 14: 379-87.
94. Petrelli NJ, Barcewicz PA, Evans JT, Ledesma EJ, Lawrence DD, Mittelman A. Hepatic artery ligation for liver metastasis in colorectal carcinoma. Cancer 1984; 53: 1347-53.
95. Hafström L, Engarås B, Holmberg SB et al. Treatment of liver metastases from colorectal cancer with hepatic artery occlusion, intraportal 5-fluorouracil infusion, and oral allopurinol. A randomized, clinical trial. Cancer 1994; 74: 2749-56.
96. Arisawa Y, Sutanto-Ward E, Fortunato L, Sigurdson ER. Hepatic artery dexamethasone infusion inhibits colorectal hepatic metastases: a regional antiangiogenic therapy. Annals of Surgical Oncology 1995; 2: 114-20.
97. Stagg RJ, Venook AP, Chase JL et al. Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst 1991; 83: 423-8.
98. Kemeny MM, Alava G, Oliver JM, Smith FB. The effects on toxicity of circadian patterning of continuous hepatic artery infusion. HPB Surg 1992; 5: 185-94.
99. Kemeny MM, Alava G, Oliver JM. The effects on liver metastases of circadian patterned continuous hepatic artery infusion of FUDR. HPB Surg 1994; 7: 219-24.
100. Wesen C, Olson G, Roemeling R et al. Circadian modified intra-arterial treatment of colo-rectal carcinoma metastatic to the liver allows higher dose intensity to be safely given. Proceedings of the American Society of Clinical Oncology 1989; 8: 105.
101. Bjarnason GA, Kerr IG, Doyle N, Macdonald M, Sone M. Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients. Cancer Chemother Pharmacol 1993; 33: 221-8.
102. Ravikumar TS, Pizzorno G, Bodden W et al. Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. J Clin Oncol 1994; 12: 2723-36.
103. Sugihara K, Hojo K, Moriya Y, Yamasaki S, Kosuge T, Takayama T. Pattern of recurrence after hepatic resection for colorectal metastases. Br J Surg 1993; 80: 1032-5.
104. Kemeny MM, Goldberg DA, Browning S, Metter GE, Miner PJ, Terz JJ. Experience with continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. A prospective randomized study. Cancer 1985; 55: 1265-70.